PRFX
PRFBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
PRF-110's comparable preclinical analgesic efficacy, potential OcuRing-K Phase II enrollment, and continued DeepSolar product development could improve the development narrative if execution advances.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
DeepSolar commercial-launch progress has not established material revenue or customer conversion.
Momentum
91
Value
59
Sentiment
29
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.10 · Bull $1.80 · Bear $0.55
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-21 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $12.00
Why
Momentum91 · Δ7d -
Value59 · Δ7d +0.2
Sentiment29 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
91
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
59
39% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
+1.2
Sentiment
29
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 91.0 / Value 58.7 / Sentiment 29.4
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$3.65M
Beta
0.60
Shares Out
3.04M
P/E (TTM)
0.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.17
Rev YoY
-
EPS YoY
+3.6%
Gross Margin
-4864.7%
Op Margin
-
Net Debt
-$4.14M
Current Ratio
1.78
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology